Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Similar articles for PubMed (Select 23316779)

1.

Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate.

Ibrahim MA, Do DV, Sepah YJ, Shah SM, Van Anden E, Hafiz G, Donahue JK, Rivers R, Balkissoon J, Handa JT, Campochiaro PA, Nguyen QD.

BMC Pharmacol Toxicol. 2013 Jan 14;14:7. doi: 10.1186/2050-6511-14-7.

2.

A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration.

Nguyen QD, Shah SM, Browning DJ, Hudson H, Sonkin P, Hariprasad SM, Kaiser P, Slakter JS, Haller J, Do DV, Mieler WF, Chu K, Yang K, Ingerman A, Vitti RL, Berliner AJ, Cedarbaum JM, Campochiaro PA.

Ophthalmology. 2009 Nov;116(11):2141-8.e1. doi: 10.1016/j.ophtha.2009.04.030. Epub 2009 Aug 22.

PMID:
19700196
3.

Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration.

Aisenbrey S, Ziemssen F, Völker M, Gelisken F, Szurman P, Jaissle G, Grisanti S, Bartz-Schmidt KU.

Graefes Arch Clin Exp Ophthalmol. 2007 Jul;245(7):941-8. Epub 2006 Dec 21.

PMID:
17186262
4.

Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.

Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA; Pan-American Collaborative Retina Study Group.

Retina. 2008 Nov-Dec;28(10):1387-94. doi: 10.1097/IAE.0b013e3181884ff4.

PMID:
18827735
5.

Comparison of 2.5 mg/kg and 5 mg/kg systemic bevacizumab in neovascular age-related macular degeneration: twenty-four week results of an uncontrolled, prospective cohort study.

Geitzenauer W, Michels S, Prager F, Rosenfeld PJ, Kornek G, Vormittag L, Schmidt-Erfurth U.

Retina. 2008 Nov-Dec;28(10):1375-86. doi: 10.1097/IAE.0b013e3181863f96.

PMID:
18784625
6.

Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study.

Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA Jr, Scott IU.

Invest Ophthalmol Vis Sci. 2006 Oct;47(10):4569-78.

PMID:
17003454
7.

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.

Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS.

Ophthalmology. 2005 Jun;112(6):1035-47.

PMID:
15936441
8.

A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.

Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG.

Ophthalmology. 2009 Sep;116(9):1731-9. doi: 10.1016/j.ophtha.2009.05.024. Epub 2009 Jul 29.

PMID:
19643495
9.

Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.

Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN.

Am J Ophthalmol. 2006 Jul;142(1):1-9.

PMID:
16815245
10.

Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.

Ahmadieh H, Taei R, Soheilian M, Riazi-Esfahani M, Karkhaneh R, Lashay A, Azarmina M, Dehghan MH, Moradian S.

BMC Ophthalmol. 2007 Jun 7;7:10.

11.

Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.

Spielberg L, Leys A.

Graefes Arch Clin Exp Ophthalmol. 2010 Jul;248(7):943-56. doi: 10.1007/s00417-009-1256-6. Epub 2010 Mar 4.

PMID:
20204659
13.

Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration.

Macugen AMD Study Group, Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Adamis AP.

Ophthalmology. 2007 Sep;114(9):1702-12. Epub 2007 May 23.

PMID:
17509689
14.

Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.

Melamud A, Stinnett S, Fekrat S.

Am J Ophthalmol. 2008 Jul;146(1):91-5. doi: 10.1016/j.ajo.2008.03.014. Epub 2008 May 2.

PMID:
18455144
15.

Pilot study of safety and effect of combined intravitreal bevacizumab and methotrexate for neovascular age-related macular degeneration.

Soheilian M, Movaseghi M, Ramezani A, Peyman GA.

Eur J Ophthalmol. 2011 Jan-Feb;21(1):77-82.

PMID:
20872362
16.

Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G.

Retina. 2006 May-Jun;26(5):495-511.

PMID:
16770255
17.

Treatment of choroidal neovascularization using intravitreal bevacizumab.

Pedersen R, Soliman W, Lund-Andersen H, Larsen M.

Acta Ophthalmol Scand. 2007 Aug;85(5):526-33. Epub 2007 May 18.

PMID:
17511757
18.

Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone.

Yip PP, Woo CF, Tang HH, Ho CK.

Br J Ophthalmol. 2009 Jun;93(6):754-8. doi: 10.1136/bjo.2008.150987. Epub 2009 Mar 8.

19.

One-year outcomes of less frequent bevacizumab in age-related macular degeneration.

Sonmez K, Sonmez PA, Ozkan SS, Atmaca LS.

Retina. 2011 Apr;31(4):645-53. doi: 10.1097/IAE.0b013e3182012d18.

PMID:
21358363
20.

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study.

Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Michels S, Marcus EN, Lenchus JD, Venkatraman AS.

Ophthalmology. 2006 Nov;113(11):2002.e1-12. Epub 2006 Oct 5.

PMID:
17027972
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk